COMPANY PROFILE

Lodo Therapeutics

Explore full profile

Drug discovery and development company

New York City, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2016

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Lodo Therapeutics

Lodo Therapeutics is a pioneering company in the field of biofacturing, leveraging advanced biological engineering to develop innovative materials for various industries. The company operates in the high-tech sector, focusing on creating new products by partnering with nature and utilizing cutting-edge bioengineering techniques. Lodo Therapeutics serves clients in the electronics, consumer care, and agriculture markets, providing them with advanced materials that meet the latest and future requirements. The business model revolves around research and development, where the company invests heavily in scientific innovation to create unique, high-value products. Revenue is generated through the commercialization of these advanced materials, which are sold to industry leaders looking for next-generation solutions. The company stands out for its ability to rethink biology and reimagine the world, making significant strides in material science and biofacturing. Keywords: biofacturing, advanced materials, electronics, consumer care, agriculture, bioengineering, innovation, high-tech, research and development, commercialization.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2015
Headquarters: New York City, United States
Employees: 8
Open positions: None listed
Dealroom signal: 80.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Genetics and genomics, Core AI, Spinout, Genome Engineering, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery
Technology: Artificial Intelligence
Client focus: b2b
Investment activity: 1 company, latest Sep 2020
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	May 2021	$0	—	Zymergen	—
SERIES A✓Equity / VC	Jan 2016	$17M	$68M	Pfizer Ventures	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Lodo Therapeutics website traffic

Latest recorded traffic for Lodo Therapeutics is 240 monthly website visits, down 42.9% over the last three months. Lodo Therapeutics's team grew 33.3% over the past year.

Latest monthly visits240 3-month web change-42.9% 1-year team growth+33.3%

Monthly website visitsOct 2017–Sep 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational	16	$20M	$14M
SYSyntekabioAI driven drug discovery and development company	Seoul, South Korea	Operational
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational
IMInSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases	Cambridge, United States	Operational
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
ADAMPLY DiscoveryNovel Biologics. Designed by Evolution. Discovered by AI	Belfast, United Kingdom	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational